Curocell
Latest round
- Series C
Last raised
- Aug 2020
Total raised
- $52M
Investors
- 18
About Curocell
Founded in 2016 and based in Daejeon, South Korea, Curocell Inc. operates as a medical technology company that researches and develops anti-cancer cell gene therapies. The company's CEO, Gunsoo Kim graduated from Yonsei University. In 2020, It completed GMP manufacturing for clinical sample production of immune cell therapy products. In 2019, it signed MOU With Samsung Seoul Hospital for joint research on immunotherapy. The company is developing OVIS™ technology to enhance immune cells and overcome immune suppression in tumor microenvironments. The company's pipelines can be categorized into CD19 CAR-T and BCMA CAR-T. The CD19 CAR-T is used to treat lymphoma patients. The BCMA CAR-T is used to treat multiple myeloma patients
Who invested in Curocell
18 investors across 3 rounds
See all investors in Curocell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Curocell
Who invested in Curocell?
Curocell has 18 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Curocell raised?
Curocell has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Curocell last raise money?
Curocell's most recent round on record is a Series C, in Aug 2020.
What does Curocell do?
Founded in 2016 and based in Daejeon, South Korea, Curocell Inc.
Where is Curocell headquartered?
Curocell is headquartered in Daejeon, South Korea.
Which VCs invest in companies like Curocell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Curocell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Curocell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.